Analysis/NN
of/IN
Gene/NN
Expression/NN
in/IN
Human/JJ
Dermal/JJ
Fibroblasts/NNS
Treated/JJ
with/IN
Senescence-Modulating/JJ
COX/NN
Inhibitors/NNS
./.
====================
We/PRP
have/VBP
previously/RB
reported/VBD
that/IN
NS-398/NN
,/,
a/DT
cyclooxygenase-2/NN
(/(
COX-2/NN
)/)
–selective/JJ
inhibitor/NN
,/,
inhibited/VBD
replicative/JJ
cellular/JJ
senescence/NN
in/IN
human/JJ
dermal/JJ
fibroblasts/NNS
and/CC
skin/NN
aging/NN
in/IN
hairless/NN
mice/NNS
./.
====================
In/IN
contrast/NN
,/,
celecoxib/JJ
,/,
another/DT
COX-2–selective/JJ
inhibitor/NN
,/,
and/CC
aspirin/NN
,/,
a/DT
non-selective/JJ
COX/NN
inhibitor/NN
,/,
accelerated/VBN
the/DT
senescence/NN
and/CC
aging/NN
./.
====================
To/TO
figure/VB
out/IN
causal/JJ
factors/NNS
for/IN
the/DT
senescence-modulating/VBG
effect/NN
of/IN
the/DT
inhibitors/NNS
,/,
we/PRP
here/RB
performed/VBN
cDNA/NN
microarray/NN
experiment/NN
and/CC
subsequent/JJ
Gene/NN
Set/NN
Enrichment/JJ
Analysis/NN
./.
====================
The/DT
data/NNS
showed/VBD
that/IN
several/JJ
senescence-related/JJ
gene/NN
sets/NNS
were/VBD
regulated/VBN
by/IN
the/DT
inhibitor/NN
treatment/NN
./.
====================
NS-398/CD
up-regulated/VBD
gene/NN
sets/NNS
involved/VBN
in/IN
the/DT
tumor/NN
necrosis/NN
factor/NN
β/NN
receptor/NN
pathway/NN
and/CC
the/DT
fructose/NN
and/CC
mannose/VBP
metabolism/NN
,/,
whereas/IN
it/PRP
down-regulated/VBD
a/DT
gene/NN
set/NN
involved/VBN
in/IN
protein/NN
secretion/NN
./.
====================
Celecoxib/NN
up-regulated/VBD
gene/NN
sets/NNS
involved/VBN
in/IN
G2M/NN
checkpoint/NN
and/CC
E2F/NN
targets/NNS
./.
====================
Aspirin/NN
up-regulated/VBD
the/DT
gene/NN
set/NN
involved/VBN
in/IN
protein/NN
secretion/NN
,/,
and/CC
down-regulated/VBN
gene/NN
sets/NNS
involved/VBN
in/IN
RNA/NN
transcription/NN
./.
====================
These/DT
results/NNS
suggest/VBP
that/IN
COX/NN
inhibitors/NNS
modulate/VBP
cellular/JJ
senescence/NN
by/IN
different/JJ
mechanisms/NNS
and/CC
will/MD
provide/VB
useful/JJ
information/NN
to/TO
understand/VB
senescence-modulating/VBG
mechanisms/NNS
of/IN
COX/NN
inhibitors/NNS
./.
====================
Prostaglandin/NN
endoperoxide/NN
synthase/NN
,/,
also/RB
called/VBN
as/IN
cyclooxygenase/NN
(/(
COX/NN
)/)
,/,
is/VBZ
an/DT
enzyme/NN
converting/VBG
arachidonic/JJ
acid/NN
to/TO
prostaglandin/NN
H2/NN
(/(
PGH2/NN
)/)
./.
====================
PGH2/NN
is/VBZ
a/DT
common/JJ
precursor/NN
for/IN
prostanoid/JJ
biosynthesis/NN
such/JJ
as/IN
PGD2/NN
,/,
PGE2/NN
,/,
PGF2α/NN
,/,
PGI2/NN
,/,
and/CC
thromboxane/NN
A2/NN
./.
====================
These/DT
prostanoids/NNS
are/VBP
known/VBN
to/TO
be/VB
important/JJ
chemical/JJ
mediators/NNS
for/IN
inflammation/NN
as/IN
well/RB
as/IN
other/JJ
biological/JJ
processes/NNS
[/(
1/CD
]/)
./.
====================
There/EX
are/VBP
two/CD
isoforms/NNS
of/IN
COX/NN
./.
====================
COX-1/NN
(/(
PTGS1/NN
)/)
is/VBZ
expressed/VBN
constitutively/RB
in/IN
most/JJS
cells/NNS
and/CC
responsible/JJ
for/IN
basal/JJ
level/NN
of/IN
prostanoid/JJ
biosynthesis/NN
./.
====================
COX-2/NN
(/(
PTGS2/NN
)/)
is/VBZ
induced/VBN
by/IN
various/JJ
stimuli/NNS
such/JJ
as/IN
bacterial/JJ
endotoxins/NNS
,/,
cytokines/NNS
,/,
genotoxic/JJ
agents/NNS
,/,
growth/NN
factors/NNS
,/,
or/CC
oncogene/NN
products/NNS
[/(
23/CD
]/)
./.
====================
Most/JJS
non-steroidal/JJ
anti-inflammatory/JJ
drugs/NNS
are/VBP
COX/NN
inhibitors/NNS
./.
====================
These/DT
drugs/NNS
inhibit/VBP
the/DT
COX/NN
catalytic/JJ
activity/NN
by/IN
occupying/VBG
the/DT
active/JJ
site/NN
of/IN
COX/NN
./.
====================
Aspirin/NN
,/,
ibuprofen/NN
,/,
or/CC
flurbiprofen/NN
is/VBZ
a/DT
non-selective/JJ
COX/NN
inhibitor/NN
,/,
which/WDT
inhibits/VBZ
both/CC
COX-1/NN
and/CC
COX-2/NN
catalytic/JJ
activity/NN
./.
====================
In/IN
contrast/NN
,/,
NS-398/NN
,/,
celecoxib/JJ
,/,
or/CC
nimesulide/NN
is/VBZ
a/DT
selective/JJ
COX-2/NN
inhibitor/NN
,/,
which/WDT
inhibits/VBZ
COX-2/NN
catalytic/JJ
activity/NN
specifically/RB
[/(
34/CD
]/)
./.
====================
The/DT
mechanism/NN
of/IN
aging/NN
has/VBZ
not/RB
been/VBN
fully/RB
understood/VBN
./.
====================
However/RB
,/,
it/PRP
has/VBZ
been/VBN
proposed/VBN
that/IN
the/DT
pro-inflammatory/JJ
catalytic/JJ
activity/NN
of/IN
COX-2/NN
is/VBZ
a/DT
causal/JJ
factor/NN
for/IN
aging/NN
./.
====================
The/DT
hypothesis/NN
proposes/VBZ
that/DT
reactive/JJ
oxygen/NN
species/NNS
(/(
ROS/NN
)/)
generated/VBD
in/IN
the/DT
process/NN
of/IN
normal/JJ
metabolism/NN
or/CC
inflammation/NN
activate/VBP
the/DT
transcription/NN
factor/NN
nuclear/JJ
factor/NN
κB/NN
(/(
NF-κB/NN
)/)
./.
====================
NF-κB/NN
increases/VBZ
the/DT
transcription/NN
of/IN
pro-inflammatory/JJ
target/NN
genes/NNS
such/JJ
as/IN
COX-2/NN
,/,
which/WDT
in/IN
turn/NN
stabilizes/VBZ
a/DT
chronic/JJ
inflammatory/JJ
circuit/NN
by/IN
generating/VBG
ROS/NN
./.
====================
This/DT
chronic/JJ
inflammation/NN
causes/VBZ
tissue/NN
damage/NN
and/CC
aging/NN
[/(
5/CD
]/)
./.
====================
If/IN
the/DT
pro-inflammatory/JJ
catalytic/JJ
activity/NN
of/IN
COX-2/NN
is/VBZ
a/DT
causal/JJ
factor/NN
for/IN
aging/NN
,/,
COX-2/NN
inhibitors/NNS
should/MD
conceivably/RB
inhibit/VBP
aging/NN
./.
====================
In/IN
this/DT
context/NN
,/,
we/PRP
have/VBP
previously/RB
examined/VBN
the/DT
effect/NN
of/IN
COX-2/NN
inhibitors/NNS
on/IN
aging/NN
both/CC
in/FW
the/DT
replicative/JJ
cellular/JJ
senescence/NN
model/NN
of/IN
human/JJ
dermal/JJ
fibroblasts/NNS
(/(
HDFs/NNS
)/)
and/CC
in/IN
the/DT
intrinsic/JJ
skin/NN
aging/NN
model/NN
of/IN
hairless/JJ
mice/NNS
./.
====================
We/PRP
observed/VBD
that/IN
among/IN
three/CD
selective/JJ
COX-2/NN
inhibitors/NNS
studied/VBD
,/,
only/RB
NS-398/NN
inhibited/VBD
the/DT
cellular/JJ
senescence/NN
whereas/IN
celecoxib/JJ
and/CC
nimesulide/NN
accelerated/VBN
the/DT
senescence/NN
./.
====================
In/IN
addition/NN
,/,
three/CD
non-selective/JJ
COX/NN
inhibitors/NNS
including/VBG
aspirin/NN
,/,
ibuprofen/NN
,/,
and/CC
flurbiprofen/NN
accelerated/VBN
the/DT
senescence/NN
[/(
6/CD
]/)
./.
====================
Also/RB
,/,
we/PRP
observed/VBD
that/IN
only/RB
NS-398/NN
inhibited/VBD
the/DT
skin/NN
aging/NN
while/IN
celecoxib/JJ
and/CC
aspirin/NN
accelerated/VBN
the/DT
skin/NN
aging/NN
in/IN
hairless/NN
mice/NNS
[/(
3/CD
]/)
./.
====================
These/DT
studies/NNS
strongly/RB
suggest/VBP
that/IN
the/DT
pro-inflammatory/JJ
catalytic/JJ
activity/NN
of/IN
COX-2/NN
is/VBZ
not/RB
a/DT
causal/JJ
factor/NN
for/IN
aging/NN
and/CC
that/IN
the/DT
aging-modulating/NN
effect/NN
of/IN
COX/NN
inhibitors/NNS
is/VBZ
attributable/JJ
to/TO
a/DT
catalytic/JJ
activity–independent/JJ
mechanism/NN
./.
====================
In/IN
an/DT
attempt/NN
to/TO
figure/NN
out/IN
underlying/VBG
mechanisms/NNS
by/IN
which/WDT
COX/NN
inhibitors/NNS
modulate/VBP
aging/NN
,/,
we/PRP
here/RB
performed/VBN
cDNA/NN
microarray/NN
experiment/JJ
and/CC
subsequent/JJ
Gene/NN
Set/NN
Enrichment/JJ
Analysis/NN
(/(
GSEA/NN
)/)
in/IN
HDFs/NNS
treated/VBN
with/IN
three/CD
COX/NN
inhibitors/NNS
,/,
NS-398/NN
,/,
celecoxib/JJ
,/,
and/CC
aspirin/NN
./.
====================
Materials/NNS
and/CC
cell/NN
culture/NN
====================
NS-398/CD
and/CC
aspirin/NN
were/VBD
purchased/VBN
from/IN
Cayman/JJ
Chemicals/NNS
(/(
Ann/NN
Arbor/NN
,/,
MI/NN
,/,
USA/NN
)/)
./.
====================
Celecoxib/NN
was/VBD
a/DT
generous/JJ
gift/NN
from/IN
Dr./NNP
S.V/NN
./.
====================
Yim/NN
(/(
Kyung/NN
Hee/JJ
University/NN
,/,
Seoul/JJ
,/,
Korea/NN
)/)
./.
====================
HDFs/NNS
,/,
isolated/VBN
from/IN
foreskin/NN
[/(
7/CD
]/)
,/,
were/VBD
cultured/VBN
in/IN
Dulbecco/NN
's/POS
modified/VBN
Eagle/JJ
's/POS
medium/NN
containing/VBG
10/CD
%/NN
fetal/JJ
bovine/NN
serum/NN
(/(
Life/NN
Technologies/NNS
,/,
Carlsbad/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
,/,
penicillin/NN
(/(
100/CD
units/mL/NN
)/)
and/CC
streptomycin/NN
(/(
100/CD
units/mL/NN
)/)
in/IN
a/DT
5/CD
%/NN
CO2/NN
incubator/NN
[/(
6/CD
]/)
./.
====================
RNA/NN
isolation/NN
====================
Total/JJ
RNA/NN
was/VBD
extracted/VBN
from/IN
HDFs/NNS
with/IN
Trizol/NN
(/(
Life/NN
Technologies/NNS
)/)
,/,
purified/VBN
with/IN
the/DT
addition/NN
of/IN
chloroform/NN
,/,
and/CC
precipitated/VBD
with/IN
the/DT
addition/NN
of/IN
isopropanol/NN
./.
====================
The/DT
RNA/NN
concentration/NN
was/VBD
determined/VBN
by/IN
spectrophotometer/NN
and/CC
the/DT
quality/NN
of/IN
RNA/NN
was/VBD
evaluated/VBN
by/IN
OD/NN
260/280/CD
ratio/NN
and/CC
gel/NN
electrophoresis/NN
[/(
8/CD
]/)
./.
====================
cDNA/NN
microarray/NN
experiment/NN
====================
The/DT
following/VBG
procedures/NNS
were/VBD
carried/VBN
out/RP
by/IN
Macrogen/NN
Co./NN
(/(
Seoul/JJ
,/,
Korea/NN
)/)
./.
====================
Five/CD
hundred/VBD
fifty/CD
nanograms/NNS
of/IN
total/JJ
RNA/NN
was/VBD
reverse-transcribed/VBN
to/TO
cDNA/NN
using/VBG
a/DT
T7/NN
oligo/JJ
(/(
dT/NN
)/)
primer/NN
./.
====================
Second-strand/CC
cDNA/NN
was/VBD
synthesized/VBN
,/,
in/IN
vitro/FW
transcribed/VBN
,/,
and/CC
labeled/VBN
with/IN
biotin-NTP/NN
./.
====================
After/IN
purification/NN
,/,
750/CD
ng/NN
of/IN
labeled/VBN
cRNA/NN
was/VBD
hybridized/VBN
to/TO
Illumina/NN
Human/JJ
HT12/NN
v.4/CD
bead/RB
array/NN
(/(
Illumina/NN
,/,
San/NNP
Diego/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
for/IN
16-18/CD
h/NN
at/IN
58oC/NN
./.
====================
The/DT
array/NN
signal/NN
was/VBD
detected/VBN
by/IN
using/VBG
Amersham/JJ
fluorolink/NN
streptavidin-Cy3/NN
(/(
GE/NN
Healthcare/JJ
Bio-Sciences/NNS
,/,
Little/JJ
Chalfont/JJ
,/,
UK/NN
)/)
./.
====================
Arrays/NNS
were/VBD
scanned/VBN
with/IN
an/DT
Illumina/NN
bead/VBD
array/NN
Reader/NN
confocal/JJ
scanner/NN
./.
====================
Array/NN
data/NNS
were/VBD
filtered/VBN
by/IN
detection/NN
p-value/NN
</JJR
0.05/CD
(/(
similar/JJ
to/TO
signal/VB
to/TO
noise/JJ
)/)
./.
====================
The/DT
average/JJ
signal/NN
values/NNS
of/IN
filtered/JJ
genes/NNS
were/VBD
transformed/VBN
by/IN
logarithm/NN
and/CC
normalized/VBD
by/IN
the/DT
quantile/JJ
method/NN
[/(
8/CD
]/)
./.
====================
Gene/NN
Set/NN
Enrichment/JJ
Analysis/NN
(/(
GSEA/NN
)/)
====================
The/DT
beta/NN
version/NN
of/IN
GSEA/NN
software/JJ
and/CC
MSigDB/NN
5.2/CD
were/VBD
downloaded/VBN
from/IN
the/DT
Broad/JJ
Institute/JJ
(/(
http/NN
:/:
//software.broadinstitute.org/gsea/index.jsp/JJ
)/)
./.
====================
GSEA/NN
was/VBD
carried/VBN
out/RP
as/IN
described/VBN
previously/RB
[/(
9/CD
]/)
./.
====================
Enrichment/JJ
of/IN
gene/NN
sets/NNS
was/VBD
considered/VBN
statistically/RB
significant/JJ
if/IN
the/DT
normalized/VBN
p-value/NN
was/VBD
</JJR
0.01/CD
and/CC
the/DT
false/NN
discovery/NN
rate/NN
(/(
FDR/NN
)/)
was/VBD
</JJR
0.20/CD
./.
====================
Treatment/NN
of/IN
HDFs/NNS
with/IN
COX/NN
inhibitors/NNS
====================
We/PRP
have/VBP
previously/RB
shown/VBN
that/IN
among/IN
COX/NN
inhibitors/NNS
studied/VBD
,/,
NS-398/NN
,/,
a/DT
COX-2-selective/JJ
inhibitor/NN
,/,
inhibited/VBD
replicative/JJ
cellular/JJ
senescence/NN
in/IN
HDFs/NNS
as/IN
well/RB
as/IN
skin/NN
aging/NN
in/IN
hairless/RB
mice/NNS
,/,
whereas/IN
celecoxib/JJ
,/,
another/DT
COX-2-selective/JJ
inhibitor/NN
,/,
and/CC
aspirin/NN
,/,
a/DT
non-selective/JJ
COX/NN
inhibitor/NN
,/,
accelerated/VBN
the/DT
senescence/NN
and/CC
aging/NN
./.
====================
At/IN
that/DT
time/NN
,/,
we/PRP
treated/VBD
cells/NNS
or/CC
skin/NN
with/IN
inhibitors/NNS
every/RB
day/NN
for/IN
more/RBR
than/IN
a/DT
month/NN
(/(
Table/JJ
1/CD
)/)
[/(
36/CD
]/)
./.
====================
To/TO
figure/VB
out/IN
causal/JJ
factors/NNS
for/IN
the/DT
senescence-modulating/VBG
effect/NN
of/IN
the/DT
inhibitors/NNS
,/,
we/PRP
treated/VBD
HDFs/NNS
with/IN
NS-398/NN
,/,
celecoxib/JJ
,/,
aspirin/NN
,/,
or/CC
dimethyl/JJ
sulfoxide/NN
(/(
DMSO/NN
)/)
(/(
the/DT
vehicle/NN
)/)
every/RB
day/NN
for/IN
only/RB
3/CD
days/NNS
in/IN
this/DT
study/NN
./.
====================
The/DT
IC50/NN
values/NNS
have/VBP
been/VBN
reported/VBN
for/IN
recombinant/JJ
human/JJ
COX-1/NN
and/CC
COX-2/NN
of/IN
NS-398/NN
and/CC
celecoxib/JJ
[/(
1011/CD
]/)
,/,
and/CC
for/IN
recombinant/JJ
ovine/NN
COX-1/NN
and/CC
COX-2/NN
of/IN
aspirin/NN
[/(
12/CD
]/)
./.
====================
In/IN
the/DT
case/NN
of/IN
NS-398/NN
and/CC
celecoxib/JJ
,/,
we/PRP
used/VBD
approximately/RB
10-fold/JJ
higher/JJR
concentration/NN
of/IN
IC50/NN
to/TO
inhibit/VB
COX-2/NN
catalytic/JJ
activity/NN
sufficiently/RB
./.
====================
NS-398/CD
and/CC
celecoxib/JJ
showed/VBD
no/DT
acute/JJ
cellular/JJ
toxicity/NN
at/IN
this/DT
concentration/NN
./.
====================
In/IN
the/DT
case/NN
of/IN
aspirin/NN
,/,
however/RB
,/,
we/PRP
used/VBD
IC50/NN
because/IN
10-fold/JJ
higher/JJR
concentration/NN
caused/VBD
acute/JJ
cellular/JJ
toxicity/NN
(/(
Table/JJ
1/CD
)/)
[/(
6/CD
]/)
./.
====================
DNA/NN
microarray/NN
and/CC
GSEA/NN
====================
We/PRP
performed/VBD
cDNA/NN
microarray/NN
experiment/NN
using/VBG
RNA/NN
extracted/VBN
from/IN
the/DT
drug-treated/JJ
HDFs/NNS
./.
====================
Among/IN
47,319/CD
probe/NN
sets/NNS
,/,
20,271/CD
probe/NN
sets/NNS
passed/VBN
the/DT
criteria/NNS
of/IN
the/DT
detection/NN
p-value/NN
</JJR
0.05/CD
./.
====================
Unsupervised/JJ
hierarchical/JJ
cluster/NN
analysis/NN
showed/VBD
that/IN
drug-treated/JJ
cells/NNS
were/VBD
well/RB
segregated/VBD
in/IN
the/DT
order/NN
of/IN
DMSO/NN
,/,
NS-398/NN
,/,
celecoxib/JJ
,/,
and/CC
aspirin/NN
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
To/TO
figure/VB
out/IN
underlying/VBG
mechanisms/NNS
by/IN
which/WDT
COX/NN
inhibitors/NNS
modulate/VBP
senescence/NN
,/,
we/PRP
performed/VBD
GSEA/NN
using/VBG
17,777/CD
probe/NN
sets/NNS
having/VBG
all/DT
information/NN
including/VBG
gene/NN
symbols/NNS
and/CC
gene/NN
descriptions/NNS
./.
====================
We/PRP
sorted/VBD
the/DT
data/NNS
sets/NNS
based/VBN
on/IN
the/DT
value/NN
of/IN
(/(
INS-398/CD
–/NNP
IDMSO/NN
)/)
for/IN
the/DT
comparison/NN
of/IN
NS-398/NN
versus/CC
DMSO/NN
;/:
the/DT
value/NN
of/IN
(/(
ICelecoxib/NN
–/NNP
IDMSO/NN
)/)
for/IN
the/DT
comparison/NN
of/IN
celecoxib/JJ
versus/CC
DMSO/NN
;/:
and/CC
the/DT
value/NN
of/IN
(/(
IAspirin/NN
–/NNP
IDMSO/NN
)/)
for/IN
the/DT
comparison/NN
of/IN
aspirin/NN
versus/CC
DMSO/NN
to/TO
rank/VB
the/DT
data/NNS
sets/NNS
as/IN
described/VBN
previously/RB
[/(
9/CD
]/)
./.
====================
We/PRP
then/RB
tested/VBN
(/(
1/LS
)/)
the/DT
Hallmark/NN
gene/NN
sets/NNS
(/(
H/NN
)/)
;/:
(/(
2/LS
)/)
gene/NN
sets/NNS
regulating/VBG
canonical/JJ
pathways—i.e./FW
,/,
Biocarta/NNP
gene/NN
sets/NNS
(/(
C2/NN
:/:
CP/NN
:/:
BIOCARTA/NNP
)/)
,/,
Kyoto/NNP
Encyclopedia/NN
of/IN
Genes/NNS
and/CC
Genomes/NNP
(/(
KEGG/NNP
)/)
gene/NN
sets/NNS
(/(
C2/NN
:/:
CP/NN
:/:
KEGG/NNP
)/)
,/,
and/CC
Reactome/NNP
gene/NN
sets/NNS
(/(
C2/NN
:/:
CP/NN
:/:
REACTOME/NNP
)/)
;/:
and/CC
(/(
3/LS
)/)
gene/NN
ontology/RB
gene/NN
sets—i.e./FW
,/,
biological/JJ
process/NN
gene/NN
sets/NNS
(/(
G5/NNP
:/:
BP/NN
)/)
,/,
cellular/JJ
component/NN
gene/NN
sets/NNS
(/(
G5/NNP
:/:
CC/NN
)/)
,/,
and/CC
molecular/JJ
function/NN
gene/NN
sets/NNS
(/(
G5/NNP
:/:
MF/NNP
)/)
./.
====================
NS-398/CD
versus/CC
DMSO/NN
====================
The/DT
analysis/NN
of/IN
NS-398/NN
versus/CC
DMSO/NN
showed/VBD
that/IN
two/CD
gene/NN
sets/NNS
are/VBP
enriched/VBN
in/IN
NS-398–treated/JJ
HDFs/NNS
as/IN
compared/VBN
with/IN
DMSO-treated/JJ
HDFs/NNS
./.
====================
These/DT
gene/NN
sets/NNS
consist/VBP
of/IN
genes/NNS
regulating/VBG
the/DT
tumor/NN
necrosis/NN
factor/NN
beta/NN
receptor/NN
(/(
TNFR2/NN
)/)
pathway/NN
and/CC
the/DT
fructose/NN
and/CC
mannose/VBP
metabolism/NN
(/(
Table/JJ
2/CD
,/,
Fig/NN
./.
====================
2A/NN
)/)
./.
====================
Enriched/VBN
genes/NNS
in/IN
each/DT
pathway/NN
were/VBD
shown/VBN
in/IN
Supplementary/JJ
Tables/NNS
1/CD
and/CC
2/CD
,/,
and/CC
Supplementary/JJ
Figs/NNS
./.
====================
1/CD
and/CC
2/CD
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
four/CD
gene/NN
sets/NNS
were/VBD
enriched/VBN
in/IN
DMSO-treated/JJ
HDFs/NNS
as/IN
compared/VBN
with/IN
NS-398–treated/JJ
HDFs/NNS
:/:
genes/NNS
down-regulated/VBN
in/IN
response/NN
to/TO
ultraviolet/JJ
(/(
UV/NN
)/)
radiation/NN
,/,
and/CC
genes/NNS
regulating/VBG
the/DT
protein/NN
secretion/NN
,/,
the/DT
trefoil/NN
factor/NN
pathway/NN
and/CC
the/DT
receptor-regulated/JJ
Smads/NNS
(/(
R-SMAD/NN
)/)
binding/VBG
(/(
Table/JJ
3/CD
,/,
Fig/NN
./.
====================
2B/NN
)/)
./.
====================
Enriched/VBN
genes/NNS
in/IN
each/DT
gene/NN
set/NN
were/VBD
shown/VBN
in/IN
Supplementary/JJ
Tables/NNS
3/CD
,/,
4/CD
,/,
5/CD
,/,
6/CD
./.
====================
Celecoxib/NN
versus/CC
DMSO/NN
====================
The/DT
analysis/NN
of/IN
celecoxib/JJ
versus/CC
DMSO/NN
showed/VBD
that/IN
four/CD
gene/NN
sets/NNS
were/VBD
enriched/VBN
in/IN
celecoxib-treated/JJ
HDFs/NNS
as/IN
compared/VBN
with/IN
DMSO-treated/JJ
HDFs/NNS
./.
====================
These/DT
gene/NN
sets/NNS
consist/VBP
of/IN
genes/NNS
involved/VBN
in/IN
the/DT
G2M/NN
checkpoint/NN
,/,
E2F/NN
targets/NNS
,/,
γ/RB
tubulin/NN
complex/NN
and/CC
the/DT
four/CD
way/NN
junction/NN
(/(
Holliday/JJ
junction/NN
)/)
DNA/NN
binding/NN
(/(
Table/JJ
4/CD
,/,
Fig/NN
./.
====================
3A/NN
)/)
./.
====================
Enriched/VBN
genes/NNS
in/IN
each/DT
gene/NN
set/NN
were/VBD
shown/VBN
in/IN
Supplementary/JJ
Tables/NNS
7/CD
,/,
8/CD
,/,
9/CD
,/,
10/CD
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
one/CD
gene/NN
set/NN
was/VBD
enriched/VBN
in/IN
DMSO-treated/JJ
HDFs/NNS
as/IN
compared/VBN
with/IN
celecoxib-treated/JJ
HDFs/NNS
./.
====================
This/DT
gene/NN
set/NN
consists/VBZ
of/IN
genes/NNS
regulating/VBG
olfactory/JJ
signaling/NN
pathway/NN
(/(
Table/JJ
5/CD
,/,
Fig/NN
./.
====================
3B/NN
)/)
./.
====================
The/DT
list/NN
of/IN
enriched/JJ
genes/NNS
in/IN
this/DT
pathway/NN
was/VBD
shown/VBN
in/IN
Supplementary/JJ
Table/JJ
11/CD
./.
====================
Aspirin/NN
versus/CC
DMSO/NN
====================
In/IN
the/DT
case/NN
of/IN
aspirin/NN
versus/CC
DMSO/NN
,/,
four/CD
gene/NN
sets/NNS
were/VBD
enriched/VBN
in/IN
aspirin-treated/JJ
HDFs/NNS
as/IN
compared/VBN
with/IN
DMSO-treated/JJ
HDFs/NNS
./.
====================
These/DT
gene/NN
sets/NNS
consist/VBP
of/IN
genes/NNS
involved/VBN
in/IN
the/DT
protein/NN
secretion/NN
,/,
keratin/NN
filament/JJ
and/CC
intermediate/JJ
filament/JJ
,/,
and/CC
genes/NNS
down-regulated/VBN
in/IN
response/NN
to/TO
UV/NN
radiation/NN
(/(
Table/JJ
6/CD
,/,
Fig/NN
./.
====================
4A/CD
)/)
./.
====================
Enriched/VBN
genes/NNS
in/IN
each/DT
gene/NN
set/NN
were/VBD
shown/VBN
in/IN
Supplementary/JJ
Tables/NNS
12/CD
,/,
13/CD
,/,
14/CD
,/,
15/CD
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
three/CD
gene/NN
sets/NNS
of/IN
C2/NN
:/:
CP/NN
were/VBD
enriched/VBN
in/IN
DMSO-treated/JJ
HDFs/NNS
as/IN
compared/VBN
with/IN
aspirin-treated/JJ
HDFs/NNS
:/:
genes/NNS
regulating/VBG
prostate/NN
cancer/NN
,/,
colorectal/JJ
cancer/NN
,/,
and/CC
cardiomyopathy/JJ
(/(
Table/JJ
7/CD
)/)
./.
====================
In/IN
addition/NN
,/,
34/CD
gene/NN
sets/NNS
of/IN
C5/NN
:/:
BP/NN
,/,
three/CD
gene/NN
sets/NNS
of/IN
C5/NN
:/:
CC/NN
and/CC
five/CD
gene/NN
sets/NNS
of/IN
C5/NN
:/:
MF/NN
were/VBD
enriched/VBN
in/IN
DMSO-treated/JJ
HDFs/NNS
as/IN
compared/VBN
with/IN
aspirin-treated/JJ
HDFs/NNS
./.
====================
These/DT
gene/NN
sets/NNS
consist/VBP
of/IN
genes/NNS
involved/VBN
in/IN
embryonic/JJ
development/NN
,/,
negative/JJ
regulation/NN
of/IN
protein/NN
localization/NN
to/TO
plasma/NN
membrane/NN
,/,
DNA-dependent/JJ
RNA/NN
transcription/NN
,/,
cell/NN
differentiation/NN
,/,
glutamate/NN
receptor/NN
binding/NN
,/,
or/CC
Smad/JJ
binding/VBG
(/(
Tables/NNS
7/CD
and/CC
8/CD
,/,
Fig/NN
./.
====================
4B/NN
)/)
./.
====================
Of/IN
note/NN
,/,
the/DT
gene/NN
set/NN
involved/VBN
in/IN
platelet/NN
aggregation/NN
was/VBD
enriched/VBN
in/IN
DMSO-treated/JJ
HDFs/NNS
as/IN
compared/VBN
with/IN
aspirin-treated/JJ
HDFs/NNS
(/(
Table/JJ
8/CD
,/,
FDR/NN
,/,
0.179/CD
)/)
./.
====================
Enriched/VBN
genes/NNS
in/IN
representative/JJ
gene/NN
sets/NNS
were/VBD
shown/VBN
in/IN
Supplementary/JJ
Tables/NNS
16/CD
,/,
17/CD
,/,
18/CD
,/,
19/CD
,/,
20/CD
,/,
21/CD
,/,
22/CD
./.
====================
Our/PRP$
data/NNS
showed/VBD
that/IN
NS-398/NN
treatment/NN
up-regulated/VBD
the/DT
gene/NN
set/NN
involved/VBN
in/IN
the/DT
TNFR2/NN
pathway/NN
(/(
Table/JJ
2/CD
,/,
Fig/NN
./.
====================
2A/NN
,/,
Supplementary/JJ
Table/JJ
1/CD
)/)
./.
====================
This/DT
pathway/NN
is/VBZ
well/RB
known/VBN
to/TO
activate/VB
the/DT
NF-κB/NN
signaling/NN
that/DT
mediates/VBZ
cell/NN
proliferation/NN
,/,
anti-apoptosis/JJ
,/,
inflammation/NN
,/,
differentiation/NN
,/,
or/CC
development/NN
(/(
Supplementary/JJ
Fig/NN
./.
====================
1/CD
)/)
[/(
13/CD
]/)
./.
====================
NF-κB/NN
,/,
a/DT
transcription/NN
factor/NN
,/,
has/VBZ
been/VBN
reported/VBN
to/TO
regulate/VB
cellular/JJ
senescence/NN
though/IN
its/PRP$
role/NN
in/IN
the/DT
senescence/NN
is/VBZ
controversial/JJ
./.
====================
Overexpression/NN
of/IN
c-Rel/NN
resulted/VBD
in/IN
premature/JJ
senescence/NN
in/IN
normal/JJ
human/JJ
keratinocytes/NNS
[/(
14/CD
]/)
./.
====================
On/IN
the/DT
contrary/NN
,/,
mouse/NN
embryonic/JJ
fibroblasts/NNS
from/IN
NF-κB1/NN
knockout/JJ
mice/NNS
showed/VBD
enhanced/VBN
cellular/JJ
senescence/NN
[/(
15/CD
]/)
./.
====================
In/IN
addition/NN
,/,
siRNA/JJ
against/IN
NF-κB2/NN
or/CC
RelB/NN
induced/VBD
premature/JJ
senescence/NN
in/IN
HDFs/NNS
in/IN
a/DT
p53-dependent/JJ
manner/NN
[/(
16/CD
]/)
./.
====================
These/DT
studies/NNS
suggest/VBP
that/IN
the/DT
anti-senescent/JJ
effect/NN
of/IN
NS-398/NN
might/MD
be/VB
attributable/JJ
to/TO
a/DT
regulation/NN
of/IN
NF-κB/NN
signaling/NN
./.
====================
NS-398/CD
treatment/NN
also/RB
up-regulated/VBD
the/DT
gene/NN
set/NN
involved/VBN
in/IN
the/DT
fructose/NN
and/CC
mannose/VBP
metabolism/NN
(/(
Table/JJ
2/CD
,/,
Supplementary/JJ
Table/JJ
2/CD
)/)
./.
====================
This/DT
metabolic/JJ
pathway/NN
leads/VBZ
to/TO
enhanced/VBN
glycolysis/NN
and/CC
N-glycan/NN
biosynthesis/NN
(/(
Supplementary/JJ
Fig/NN
./.
====================
2/CD
)/)
./.
====================
Alterations/NNS
of/IN
glucose/NN
metabolism/NN
have/VBP
been/VBN
reported/VBN
in/IN
cellular/JJ
senescence/NN
though/IN
the/DT
data/NNS
is/VBZ
conflicting/VBG
./.
====================
In/IN
human/JJ
mammary/JJ
epithelial/JJ
cells/NNS
,/,
B-Raf–induced/JJ
premature/JJ
senescence/NN
was/VBD
associated/VBN
with/IN
a/DT
reduction/NN
of/IN
glucose/NN
uptake/NN
,/,
and/CC
overexpression/NN
of/IN
hexokinase/NN
2/CD
prevented/VBD
the/DT
oncogene-induced/JJ
senescence/NN
[/(
17/CD
]/)
./.
====================
On/IN
the/DT
contrary/NN
,/,
glucose/NN
consumption/NN
and/CC
hexokinase/NN
activity/NN
were/VBD
increased/VBN
in/IN
senescent/JJ
HDFs/NNS
as/IN
compared/VBN
to/TO
young/JJ
HDFs/NNS
[/(
18/CD
]/)
./.
====================
These/DT
studies/NNS
suggest/VBP
that/IN
NS-398/NN
might/MD
delay/VB
cellular/JJ
senescence/NN
via/IN
regulation/NN
of/IN
glycolysis/NN
./.
====================
It/PRP
is/VBZ
intriguing/JJ
that/DT
the/DT
gene/NN
set/NN
involved/VBN
in/IN
protein/NN
secretion/NN
is/VBZ
down-regulated/VBN
by/IN
NS-398/NN
treatment/NN
but/CC
is/VBZ
up-regulated/VBN
by/IN
aspirin/NN
treatment/NN
(/(
Tables/NNS
3/CD
and/CC
6/CD
,/,
Figs/NNS
./.
====================
2B/NN
and/CC
4A/NN
,/,
Supplementary/JJ
Tables/NNS
4/CD
and/CC
12/CD
)/)
./.
====================
It/PRP
has/VBZ
been/VBN
reported/VBN
that/IN
cellular/JJ
senescence/NN
is/VBZ
accompanied/VBN
by/IN
an/DT
increase/NN
in/IN
the/DT
secretion/NN
of/IN
intercellular/JJ
signaling/NN
molecules/NNS
including/VBG
interleukins/NNS
,/,
chemokines/NNS
,/,
growth/NN
factors/NNS
,/,
proteases/NNS
,/,
and/CC
extracellular/JJ
matrix/NN
proteins/NNS
[/(
1920/CD
]/)
./.
====================
For/IN
example/NN
,/,
production/NN
of/IN
interleukin-1/NN
,/,
-6/CD
,/,
chemokine/NN
(/(
C-C/NN
motif/NN
)/)
ligand-1/NN
,/,
-2/CD
,/,
-3/CD
,/,
-7/CD
,/,
-8/CD
,/,
-12/CD
,/,
-13/CD
,/,
-16/CD
,/,
-20/CD
,/,
-26/CD
,/,
chemokine/NN
(/(
C-X-C/NN
motif/NN
)/)
ligand-1/NN
,/,
-2/CD
,/,
-4/CD
,/,
-5/CD
,/,
-6/CD
,/,
-8/CD
,/,
insulin-like/RB
growth/NN
factor/NN
binding/VBG
protein-2/NN
,/,
-3/CD
,/,
-4/CD
,/,
-5/CD
,/,
-6/CD
,/,
-7/CD
,/,
connective/JJ
tissue/NN
growth/NN
factor/NN
,/,
granulocyte-macrophage/JJ
colony-stimulating/JJ
factor/NN
,/,
granulocyte/NN
colony/NN
stimulating/VBG
factor/NN
,/,
matrix/RB
metalloproteinase-1/NN
,/,
-3/CD
,/,
-10/CD
,/,
plasminogen/RB
activator/NN
inhibitor/NN
1/LS
,/,
or/CC
fibronectin/NN
increased/VBD
in/IN
senescent/JJ
HDFs/NNS
as/IN
compared/VBN
to/TO
in/IN
young/JJ
HDFs/NNS
[/(
21/CD
]/)
./.
====================
Ectopic/JJ
expression/NN
of/IN
chemokine/NN
receptors/NNS
such/JJ
as/IN
CXCR1/NN
or/CC
CXCR2/NN
induced/VBD
premature/JJ
senescence/NN
in/IN
HDFs/NNS
[/(
22/CD
]/)
./.
====================
Extracellular/JJ
matrix/NN
from/IN
young/JJ
HDFs/NNS
restored/VBD
senescent/JJ
HDFs/NNS
to/TO
an/DT
apparently/RB
youthful/JJ
state/NN
[/(
23/CD
]/)
./.
====================
In/IN
addition/NN
,/,
there/EX
is/VBZ
a/DT
report/NN
that/IN
p16-induced/JJ
senescence/NN
is/VBZ
accompanied/VBN
by/IN
an/DT
increase/NN
in/IN
the/DT
glucose-stimulated/JJ
insulin/NN
secretion/NN
in/IN
mouse/NN
and/CC
human/JJ
pancreatic/JJ
beta/NN
cells/NNS
[/(
24/CD
]/)
./.
====================
These/DT
studies/NNS
suggest/VBP
that/IN
regulation/NN
of/IN
protein/NN
secretion/NN
might/MD
be/VB
an/DT
important/JJ
common/JJ
mechanism/NN
by/IN
which/WDT
NS-398/NN
delays/VBZ
but/CC
aspirin/NN
accelerates/VBZ
cellular/JJ
senescence/NN
./.
====================
In/IN
addition/NN
to/TO
the/DT
up-regulation/NN
of/IN
protein/NN
secretion/NN
,/,
aspirin/NN
down-regulated/VBN
gene/NN
sets/NNS
involved/VBN
in/IN
DNA-dependent/JJ
RNA/NN
transcription/NN
(/(
Table/JJ
7/CD
,/,
FDR/NN
,/,
0.062/CD
and/CC
0.088/CD
;/:
Table/JJ
8/CD
,/,
FDR/NN
,/,
0.061/CD
and/CC
0.197/CD
;/:
Fig/NN
./.
====================
4B/NN
)/)
./.
====================
Compatible/JJ
with/IN
these/DT
results/NNS
,/,
a/DT
cDNA/NN
microarray/NN
study/NN
reported/VBD
that/IN
genes/NNS
involved/VBN
in/IN
transcription/NN
were/VBD
down-regulated/VBN
specifically/RB
during/IN
senescence/NN
in/IN
HDFs/NNS
[/(
25/CD
]/)
./.
====================
In/IN
addition/NN
,/,
there/EX
is/VBZ
a/DT
report/NN
that/IN
RNA/NN
transcription/NN
was/VBD
decreased/VBN
in/IN
aged/JJ
rat/NN
brain/NN
as/IN
compared/VBN
to/TO
in/IN
young/JJ
rat/NN
brain/NN
[/(
26/CD
]/)
./.
====================
Therefore/RB
,/,
aspirin/NN
might/MD
accelerate/VB
cellular/JJ
senescence/NN
by/IN
downregulation/NN
of/IN
DNA-dependent/JJ
RNA/NN
transcription/NN
./.
====================
It/PRP
is/VBZ
well/RB
known/VBN
that/IN
aspirin/NN
inhibits/VBZ
platelet/NN
aggregation/NN
and/CC
thereby/RB
thrombus/IN
formation/NN
[/(
27/CD
]/)
./.
====================
Consistent/JJ
with/IN
this/DT
,/,
our/PRP$
data/NNS
showed/VBD
that/IN
the/DT
gene/NN
set/NN
involved/VBN
in/IN
platelet/NN
aggregation/NN
was/VBD
down-regulated/VBN
by/IN
aspirin/NN
treatment/NN
(/(
Table/JJ
8/CD
,/,
FDR/NN
,/,
0.179/CD
)/)
./.
====================
Cyclin-dependent/JJ
kinase/NN
inhibitors/NNS
(/(
CKIs/NNS
)/)
are/VBP
categorized/VBN
into/IN
two/CD
families/NNS
,/,
that/DT
is/VBZ
,/,
the/DT
Ink4/NN
family/NN
including/VBG
p15/NN
,/,
p16/NN
,/,
p18/NN
,/,
and/CC
p19/NN
,/,
and/CC
the/DT
Cip/Kip/NN
family/NN
including/VBG
p21/NN
,/,
p27/NN
,/,
and/CC
p57/NN
./.
====================
It/PRP
has/VBZ
been/VBN
reported/VBN
that/IN
these/DT
CKIs/NNS
are/VBP
actively/RB
involved/VBN
in/IN
cellular/JJ
senescence/NN
./.
====================
For/IN
example/NN
,/,
ectopic/JJ
expression/NN
of/IN
p15/NN
,/,
p16/NN
,/,
p19/NN
,/,
p21/NN
,/,
or/CC
p27/NN
was/VBD
reported/VBN
to/TO
induce/VB
premature/JJ
senescence/NN
in/IN
HDFs/NNS
[/(
2829/CD
]/)
./.
====================
According/VBG
to/TO
our/PRP$
data/NNS
,/,
celecoxib/JJ
treatment/NN
up-regulated/VBD
gene/NN
sets/NNS
relating/VBG
G2M/NN
checkpoint/NN
and/CC
E2F/NN
targets/NNS
(/(
Table/JJ
4/CD
,/,
Fig/NN
./.
====================
3A/NN
)/)
./.
====================
In/IN
addition/NN
,/,
CDKN1B/NN
encoding/VBG
p27/NN
and/CC
CDKN2C/NN
encoding/VBG
p18/NN
were/VBD
enriched/VBN
in/IN
both/DT
gene/NN
sets/NNS
(/(
Supplementary/JJ
Table/JJ
7/CD
,/,
Running/VBG
enrichment/JJ
score/RB
[/(
ES/NN
]/)
,/,
0.410/CD
and/CC
0.274/CD
;/:
Supplementary/JJ
Table/JJ
8/CD
,/,
Running/VBG
ES/NN
,/,
0.299/CD
and/CC
0.193/CD
)/)
./.
====================
These/DT
data/NNS
suggest/VBP
that/IN
celecoxib/JJ
might/MD
accelerate/VB
cellular/JJ
senescence/NN
through/IN
up-regulation/NN
of/IN
CKIs/NNS
./.
====================
Collectively/RB
,/,
our/PRP$
results/NNS
suggest/VBP
that/IN
COX/NN
inhibitors/NNS
modulate/VBP
cellular/JJ
senescence/NN
by/IN
different/JJ
mechanisms/NNS
though/IN
they/PRP
have/VBP
the/DT
anti-catalytic/JJ
activity/NN
commonly/RB
./.
====================
We/PRP
believe/VBP
that/IN
our/PRP$
study/NN
will/MD
provide/VB
useful/JJ
information/NN
to/TO
understand/VB
senescence-modulating/VBG
mechanisms/NNS
of/IN
COX/NN
inhibitors/NNS
./.
====================
Segregation/NN
between/IN
the/DT
drug-treated/JJ
HDFs/NNS
./.
====================
Unsupervised/JJ
hierarchical/JJ
cluster/NN
analysis/NN
was/VBD
done/VBN
between/IN
four/CD
drug-treated/JJ
HDFs/NNS
using/VBG
20,271/CD
probe/NN
sets/NNS
with/IN
the/DT
detection/NN
p-value/NN
</JJR
0.05/CD
./.
====================
Enrichment/JJ
plots/NNS
(/(
NS-398/NN
vs./CC
DMSO/NN
)/)
./.
====================
(/(
A/NN
)/)
A/NN
representative/JJ
enriched/JJ
gene/NN
set/NN
in/IN
NS-398–treated/JJ
HDFs/NNS
./.
====================
(/(
B/NN
)/)
A/NN
representative/JJ
enriched/JJ
gene/NN
set/NN
in/IN
DMSO-treated/JJ
HDFs/NNS
./.
====================
DMSO/NN
,/,
dimethyl/JJ
sulfoxide/NN
;/:
HDF/NN
,/,
human/JJ
dermal/JJ
fibroblast/NN
./.
====================
Enrichment/JJ
plots/NNS
(/(
celecoxib/JJ
vs./CC
DMSO/NN
)/)
./.
====================
(/(
A/NN
)/)
A/NN
representative/JJ
enriched/JJ
gene/NN
set/NN
in/IN
celecoxib–treated/JJ
HDFs/NNS
./.
====================
(/(
B/NN
)/)
The/DT
representative/JJ
enriched/JJ
gene/NN
set/NN
in/IN
DMSO-treated/JJ
HDFs/NNS
./.
====================
DMSO/NN
,/,
dimethyl/JJ
sulfoxide/NN
;/:
HDF/NN
,/,
human/JJ
dermal/JJ
fibroblast/NN
./.
====================
Enrichment/JJ
plots/NNS
(/(
aspirin/NN
vs./CC
DMSO/NN
)/)
./.
====================
(/(
A/NN
)/)
A/NN
representative/JJ
enriched/JJ
gene/NN
set/NN
in/IN
aspirin-treated/JJ
HDFs/NNS
./.
====================
(/(
B/NN
)/)
A/NN
representative/JJ
enriched/JJ
gene/NN
set/NN
in/IN
DMSO-treated/JJ
HDFs/NNS
./.
====================
DMSO/NN
,/,
dimethyl/JJ
sulfoxide/NN
;/:
HDF/NN
,/,
human/JJ
dermal/JJ
fibroblast/NN
./.
====================
Summary/JJ
of/IN
senescence-modulating/VBG
effect/NN
of/IN
COX/NN
inhibitors/NNS
and/CC
used/VBN
doses/NNS
====================
Enriched/VBN
gene/NN
sets/NNS
in/IN
NS-398–treated/JJ
HDFs/NNS
(/(
NS-398/NN
vs./CC
DMSO/NN
)/)
====================
Enriched/VBN
gene/NN
sets/NNS
in/IN
DMSO-treated/JJ
HDFs/NNS
(/(
NS-398/NN
vs./CC
DMSO/NN
)/)
====================
Enriched/VBN
gene/NN
sets/NNS
in/IN
celecoxib-treated/JJ
HDFs/NNS
(/(
celecoxib/JJ
vs./CC
DMSO/NN
)/)
====================
Enriched/VBN
gene/NN
sets/NNS
in/IN
DMSO-treated/JJ
HDFs/NNS
(/(
celecoxib/JJ
vs./CC
DMSO/NN
)/)
(/(
C2/NN
:/:
Reactome/NN
)/)
====================
Enriched/VBN
gene/NN
sets/NNS
in/IN
aspirin-treated/JJ
HDFs/NNS
(/(
aspirin/NN
vs./CC
DMSO/NN
)/)
====================
Enriched/VBN
gene/NN
sets/NNS
in/IN
DMSO-treated/JJ
HDFs/NNS
(/(
aspirin/NN
vs./CC
DMSO/NN
)/)
====================
Enriched/VBN
gene/NN
sets/NNS
in/IN
DMSO-treated/JJ
HDFs/NNS
(/(
aspirin/NN
vs./CC
DMSO/NN
)/)
(/(
C5/NN
:/:
BP/NN
)/)
====================
